Fulvestrant/AI

DRUG3 trials

Sponsors

Fudan University, Zhimin Shao

Conditions

Breast Cancer Metastatic

Phase 2

PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer

RecruitingNCT05759546

Fudan UniversityBreast Cancer Metastatic

Start: 2023-02-01End: 2027-06-01Target: 200Updated: 2024-02-06

Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer

Active, not recruitingNCT05759572

Fudan UniversityBreast Cancer Metastatic

Start: 2023-03-01End: 2027-07-01Target: 145Updated: 2026-09-16

Phase 3

PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer

Active, not recruitingNCT06612814

Zhimin ShaoBreast Cancer Metastatic

Start: 2024-09-01End: 2028-04-30Target: 307Updated: 2024-09-25

Related Papers

Influence of precision treatment with artificial intelligence–assisted subtyping on first-line therapeutic efficacy in HR+/HER2– breast cancer.

Journal of Clinical Oncology2026-05-28